The Precision Cancer Consortium (PCC) announced its formation as a new collaboration of pharmaceutical companies with a shared vision of enabling access to comprehensive testing for all cancer patients globally.

Pfizer indicated that the company’s Phase III clinical trial of 44,000 volunteers with partner BioNTech needed less than 2,000 people to be fully enrolled.